UK start-up Anifera aims to complete formulation work on its lead compound for bovine mastitis in the first half of 2022. The company was founded in 2020 as part of Stonehaven Incubate and is focused on developing adjunct therapies to improve the efficacy of veterinary antibiotics.

Anifera awarded seed funding for research from UK’s Centre for Innovation Excellence in Livestock (CIEL) • Funding will enable Anifera to investigate efficacy of their leading compound to enhance antibiotic treatment for bovine mastitis, a significant economic and welfare challenge for the global dairy industry • Data will support development of a commercialisation plan

Anifera receives further investment from Stonehaven Incubate to initiate additional studies of adjunct therapy in bovine mastitis • Bovine mastitis is a major economic and welfare challenge for the global dairy industry, reducing both milk yield and quality • Anifera’s unique mode of action aims to improve antibiotic efficacy and ultimately reduce the

Anifera, a new animal health company which aims to be the innovator and leader in researching and developing solutions for adjunct therapy with antibiotics, has announced an experienced line-up for its board.